Pharmacy Medical News about Sumavel DosePro; sumatriptan; needle-free, subcutaneous injectable formulation

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Sumatriptan (Sumavel DosePro): Needle-free injection of 5-HT1 receptor agonist approved for the acute treatment of migraine and cluster headaches
Formulary , 09/10/09

Sumatriptan is a selective agonist of 5–HT1B and 5–HT1D receptors. It has been suggested that the binding of sumatriptan to these receptors induces vasoconstriction. This needle–free, subcutaneous (SC) injectable formulation of sumatriptan was approved on July 15, 2009, for the acute treatment of migraine attacks with or without aura and for the acute treatment of cluster headache episodes...SC sumatriptan should be self–administered by the patient only to the abdomen or thigh. One unit of this agent (containing sumatriptan 6 mg) should be administered; the maximum recommended dose over 24 hours is 2 doses (units) separated by >=1 hour. The dose should not be administered within 2 inches of the navel. Each unit is for single use only.

<< Previous
Chinese herbal remedy may be better than sulfasalazine for active...

Next >>
The In Vitro Antimicrobial Activities of the Essential Oils of...